Log In Sign up
The largest database of trusted experimental protocols

Brigatinib

Manufactured by Selleck Chemicals
Visit Supplier
Sourced in United States

Brigatinib is a lab equipment product used for research purposes. It is a tyrosine kinase inhibitor that targets the anaplastic lymphoma kinase (ALK) protein. The core function of Brigatinib is to inhibit the activity of the ALK protein, which is involved in the growth and spread of certain types of cancer cells.

Automatically generated - may contain errors

Lab products found in correlation

Lorlatinib, by Selleck Chemicals (6 mentions) Crizotinib, by Selleck Chemicals (6 mentions) Alectinib, by Selleck Chemicals (4 mentions) Ceritinib, by Selleck Chemicals (4 mentions) Entrectinib, by Selleck Chemicals (3 mentions) Countess 2, by Thermo Fisher Scientific (3 mentions) Afatinib, by Selleck Chemicals (2 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (2 mentions) Repotrectinib, by Selleck Chemicals (1 mentions) Gilteritinib, by Selleck Chemicals (1 mentions) Nih3t3 cells, by American Type Culture Collection (1 mentions) Hrp conjugated goat anti rabbit igg, by Merck Group (1 mentions) Donkey anti goat igg, by Merck Group (1 mentions) Goat anti mouse igg, by Merck Group (1 mentions) Anti parp, by Cell Signaling Technology (1 mentions) Cycloheximide (chx), by Merck Group (1 mentions) Horseradish peroxidase, by Merck Group (1 mentions) Erlotinib, by Chemietek (1 mentions) Cabozantinib, by Selleck Chemicals (1 mentions) Hrp conjugated anti rabbit antibody, by Cell Signaling Technology (1 mentions)

12 protocols using brigatinib

1

Cell Line Maintenance and Compound Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
NIH3T3 cells were purchased from American Type Culture Collection (ATCC). Ba/F3, WEHI, and BOSC23 cells were kindly provided by Dr. Daniel G. Tenen (Harvard Medical School). Crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, entrectinib, gilteritinib, and repotrectinib were purchased from Selleck. NIH3T3 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 mg/ml streptomycin (P/S). Parental Ba/F3 cells were maintained in RPMI1640 supplemented with 5% WEHI (as a source of IL-3), 10% FBS, and P/S. Ba/F3 cells expressing CLIP1-LTK mutants were maintained in RPMI1640 supplemented with 10% FBS and P/S. All cell lines were routinely tested for mycoplasma infection and negative for mycoplasma infection.
Mori S., Izumi H., Araki M., Liu J., Tanaka Y., Kagawa Y., Sagae Y., Ma B., Isaka Y., Sasakura Y., Kumagai S., Sakae Y., Tanaka K., Shibata Y., Udagawa H., Matsumoto S., Yoh K., Okuno Y., Goto K, & Kobayashi S.S. (2024). LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion. Communications Biology, 7, 412.
+ Open protocol
+ Expand
2

Fetal Bovine Serum and Cell Signaling Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fetal bovine serum and culture media were purchased from Life Technologies (Grand Island, NY, USA). All antibodies were purchased from commercial sources, as indicated below. Cell Signaling Technology (Danvers, MA, USA): anti-phospho-EGFR (Y1068), anti-phospho-AXL (Y702), anti-AXL, anti-phospho-AKT (S473), anti-phospho-ERK (T202/Y204), and anti-PARP (# 9541). Santa Cruz Biotechnology Inc. (Dallas, TX, USA): anti-EGFR (1005), anti-AKT (H-136), anti-ERK (K-23), and horseradish peroxidase (HRP)-conjugated goat-anti-rabbit IgG, goat-anti-mouse IgG, and donkey-anti-goat IgG. Quercetin (CAS 6151-25-3) and cycloheximide were purchased from Sigma-Aldrich (St. Louis, MO, USA). The purity of quercetin was at least 95%, as determined by high-performance liquid chromatography analysis. Brigatinib was purchased from Selleckchem (Houston, TX, USA).
Huang K.Y., Wang T.H., Chen C.C., Leu Y.L., Li H.J., Jhong C.L, & Chen C.Y. (2021). Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin. Biomolecules, 11(9), 1271.
+ Open protocol
+ Expand
3

Small Molecule Inhibitor Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Crizotinib, ceritinib, brigatinib, cabozantinib and afatinib were purchased from Selleck Chemicals (Houston, TX, USA); gefitinib and cetuximab were purchased from Eveleth (Eveleth, MN, USA); erlotinib was purchased from Chemie Tek (Indianapolis, IN, USA); lorlatinib was purchased from Toronto Research Chemicals (Toronto, ON, Canada; and gilteritinib was purchased from Cayman Chemical (Ann Arbor, MI, USA). Recombinant HB‐EGF, EGF, FGF and IGF were purchased from R&D Systems (Minneapolis, MN, USA).
Antibodies against ROS1, phospho‐specific (p) ROS1 (Tyr2274), EGFR, pEGFR (Tyr1068), mitogen‐activated protein kinase (MAPK), pMAPK (Thr202/Tyr204), AKT, pAKT (Ser473), AXL and glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH), and HRP‐conjugated antirabbit antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA).
Kato Y., Ninomiya K., Ohashi K., Tomida S., Makimoto G., Watanabe H., Kudo K., Matsumoto S., Umemura S., Goto K., Ichihara E., Ninomiya T., Kubo T., Sato A., Hotta K., Tabata M., Toyooka S., Maeda Y, & Kiura K. (2018). Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions. Cancer Science, 109(10), 3149-3158.
+ Open protocol
+ Expand
4

Comprehensive Oncology Protein Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Saracatinib (AZD0530) and vistusertib (AZD2014) were provided by AstraZeneca. Crizotinib (S1068), alectinib (S2762), brigatinib (S8229), dasatinib (S1021), erdafitinib (S8401), debio-1347 (S7665), lorlatinib (S7536) and entrectinib (S7998) were purchased from Selleck Chemicals.
For Western Blot assays the antibodies used were: pALK Y1282/1283 (9687S), pALK Y1604 (3341S), ALK (#3333S), pAKT (#4060S), AKT (#4961S), pERK (9101S), ERK (9102S), pS6 (4858S), S6 (2217S), cleaved Parp (9541S), BIM (2933S), Merlin (1288S), pPaxillin (2541S), Paxillin (2542S), Snail (3879S) and Vimentin (5741S) purchased from Cell Signaling Technology.
For IHC assays the antibodies used were ALK (#6679072001), E-Cadh (#790-4497) and CD31 (#760-4378) purchased from Ventana; N-Cadh (#M3613), Ki-67 (#M7240), beta catenin (#M3539), podoplanin (#M3619) and CD68 (#M0814) purchased from DAKO; Vimentin (#790-2917) purchased from Roche; pSRC (#6943S) and pMAPK (#4376) purchased from Cell Signaling Technology; Glut1 (#RP128-05) purchased from Clinisciences; CA-IX (#NB100-417SS) purchased from NovusBio, NF2/Merlin purchased from Sigma-aldrich (#HPA003097) and CD47 (#M5792) purchased from Spring.
Recondo G., Mezquita L., Facchinetti F., Planchard D., Gazzah A., Bigot L., Rizvi A.Z., Frias R.L., Thiery J.P., Scoazec J.Y., Sourisseau T., Howarth K., Deas O., Samofalova D., Galissant J., Tesson P., Braye F., Naltet C., Lavaud P., Mahjoubi L., Abou Lovergne A., Vassal G., Bahleda R., Hollebecque A., Nicotra C., Ngo-Camus M., Michiels S., Lacroix L., Richon C., Auger N., De Baere T., Tselikas L., Solary E., Angevin E., Eggermont A., André F., Massard C., Olaussen K.A., Soria J.C., Besse B, & Friboulet L. (2019). Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(1), 242-255.
+ Open protocol
+ Expand
5

Immunoblotting of Cell and Tumor Lysates

Check if the same lab product or an alternative is used in the 5 most similar protocols
All NB cell lines were cultured in RPMI 1640 or Dulbecco's modified Eagle's medium with 10% foetal bovine serum and 1% penicillin and streptomycin. Immunoblotting of cell lysates was performed as described in Van den Eynden et al (2018). Mouse tumour samples were lysed according to the manufacturer's instructions (Qiagen, cat. #85300). Protein concentration was measured using BCA assay (Pierce; #23225), and proteins subsequently separated on 7.5% bis‐acryl‐tris gels, and transferred to polyvinylidene difluoride membranes (Millipore, cat.# IPVH00010). After blocking in 5% bovine serum albumin (BSA; phosphoprotein blots) or 5% milk, and incubation with primary antibodies (detailed in Table EV5) overnight at 4°C, secondary antibodies (detailed in Table EV5) were added for 1 h at RT. Enhanced chemiluminescence substrates were used for detection (GE Healthcare, cat.# RPN2232). Lorlatinib and brigatinib were from Selleckchem.
Borenäs M., Umapathy G., Lai W., Lind D.E., Witek B., Guan J., Mendoza‐Garcia P., Masudi T., Claeys A., Chuang T., El Wakil A., Arefin B., Fransson S., Koster J., Johansson M., Gaarder J., Van den Eynden J., Hallberg B, & Palmer R.H. (2021). ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation. The EMBO Journal, 40(3), e105784.
+ Open protocol
+ Expand
6

Murine Cell Lines for EGFR Inhibitor Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
The murine pro-B cell line Ba/F3 (RCB0805) and myelomonocytic, macrophage-like, BALB/C mouse leukemia cells (WEHI-3) were provided by the RIKEN Bio Resource Center (Tsukuba, Japan). Ba/F3 cells were maintained in RPMI1640 medium (Fujifilm Wako Pure Chemical Corporation), supplemented with 10% FBS (Gibco BRL), 1% penicillin-streptomycin (Fujifilm Wako Pure Chemical Corporation), and conditioned media from WEHI-3 (10%) as a source of IL3, and cultured at 37°C in a humid atmosphere with 5% CO2. Cell lines A-431, A549, NCI-H1299, and NCI-H2073 were obtained from ATCC, and the LoVo cell line was obtained from European Collection of Authenticated Cell Cultures. BBT-176 was synthesized by Wuxi AppTec (Changzhou, China). First- to third-generation EGFR TKI [erlotinib (catalog No. S7786), afatinib (S1011), dacomitinib (S2727), and osimertinib (S7297)], brigatinib (S8229; a multi-kinase inhibitor active against mutant EGFR), and the anti-EGFR antibody cetuximab (A2000) were purchased from Selleck Chemicals; cetuximab was stored at 4°C. Each TKI was dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich) and preserved at −80°C.
Lim S.M., Fujino T., Kim C., Lee G., Lee Y.H., Kim D.W., Ahn J.S., Mitsudomi T., Jin T, & Lee S.Y. (2023). BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer. Clinical Cancer Research, 29(16), 3004-3016.
+ Open protocol
+ Expand
7

Propagating PDX Neurospheres for Drug Screening

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
PDXs were propagated as neurospheres, cultured in PDX media (DMEM/F12) (50/50 with 2% B27, 20 ng/mL EGF, 20 ng/mL basic FGF, 1% sodium pyruvate, 1% penicillin and streptomycin) similar to our prior reports (57 (link)). Neurospheres were dissociated for 20 minutes with Accutase (Innovative Cell Technologies) at 37°C, viability-quantified with trypan blue utilizing the Countess II (Thermo Fisher Scientific), and plated at 500–1500 viable cells per 100 μL for 24 hours prior to treatment with indicated doses of brigatinib and sitravatinib (Selleckchem). After 7 days, CTG reagent (Promega) was added at 20 μL per well for 30 minutes at 37°C, prior to reading luminescence on the BioTek Synergy H1 (Agilent). Raw values were corrected to untreated (DMSO) control.
Stackhouse C.T., Anderson J.C., Yue Z., Nguyen T., Eustace N.J., Langford C.P., Wang J., Rowland JR I.V., Xing C., Mikhail F.M., Cui X., Alrefai H., Bash R.E., Lee K.J., Yang E.S., Hjelmeland A.B., Miller C.R., Chen J.Y., Gillespie G.Y, & Willey C.D. (2022). An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases. JCI Insight, 7(16), e148717.
+ Open protocol
+ Expand
8

Investigating Combination Therapies in Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
Curcumin (S1848), lapatinib (S2111), brigatinib (S8229), MK-0752 (S2660), sapitinib (S2192), and WP1066 (S2796) were all purchased from SellekChem. Cobimetinib (HY-13064), selumetinib (HY-50706), alpelisib (HY-15244), and trametinib (HY-10999) were purchased from MedChemExpress. Rapamycin (SC3504A) was acquired from SantaCruz Biotechnology and curcuplex-95 from Xymogen.
Allaf A., Victoria B., Rosario R., Misztal C., Humayun Gultekin S., Dinh C.T, & Fernandez-Valle C. (2022). WP1066 induces cell death in a schwannomatosis patient–derived schwannoma cell line. Cold Spring Harbor Molecular Case Studies, 8(4), a006178.
+ Open protocol
+ Expand
9

Cell Line Acquisition and Drug Procurement

Check if the same lab product or an alternative is used in the 5 most similar protocols
NIH3T3 and Phoenix-AMPHO cells were purchased from ATCC. Ba/F3, WEHI, and BOSC23 cells were kindly provided by Dr. Daniel G. Tenen (Harvard Medical School). PC9 cells were kindly provided by Dr. Pasi Jänne (Dana Farber Cancer Institute). Crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, entrectinib, and reptrectinib were purchased from Selleck.
Izumi H., Matsumoto S., Liu J., Tanaka K., Mori S., Hayashi K., Kumagai S., Shibata Y., Hayashida T., Watanabe K., Fukuhara T., Ikeda T., Yoh K., Kato T., Nishino K., Nakamura A., Nakachi I., Kuyama S., Furuya N., Sakakibara-Konishi J., Okamoto I., Taima K., Ebi N., Daga H., Yamasaki A., Kodani M., Udagawa H., Kirita K., Zenke Y., Nosaki K., Sugiyama E., Sakai T., Nakai T., Ishii G., Niho S., Ohtsu A., Kobayashi S.S, & Goto K. (2021). The CLIP1-LTK fusion is an oncogenic driver in non-small cell lung cancer. Nature, 600(7888), 319-323.
+ Open protocol
+ Expand
10

Kinase Inhibitors for Cancer Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Brigatinib (AP26113), cabozantinib (XL184), ceritinib (LDK378),
crizotinib (PF-02341066), entrectinib (RXDX-101), foretinib (GSK1363089), and
cycloheximide were purchased from Selleckchem. Lorlatinib (PF-6463922) and
repotrectinib (TPX-0005) were purchased from MedChem Express.
Keddy C., Shinde P., Jones K., Kaech S., Somwar R., Shinde U, & Davare M.A. (2021). Resistance profile and structural modeling of next-generation ROS1 tyrosine kinase inhibitors. Molecular cancer therapeutics, 21(2), 336-346.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!